公开(公告)号：EP1283735B1

公开(公告)日：2008-12-31

申请号：EP01927848.0

申请日：2001-04-02

申请人： Prosidion Limited

发明人： DEMUTH, Hans-Ulrich ,  GLUND, Konrad

IPC分类号： A61P3/10 ,  A61K31/00 ,  A61K31/40 ,  A61K31/426

CPC分类号： A61K45/06 ,  A61K31/00 ,  A61K31/40 ,  A61K31/426 ,  Y10S514/866

摘要： The present invention discloses a method for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic β-cells and to cause differentiation of pancreatic epithelial cells into insulin producing β-cells. Oral administration of a DP IV inhibitor causes the active form of GLP-1 to be preserved longer under physiological conditions. The extended presence of GLP-1, in particular in the pancreatic tissue facilitates differentiation and regeneration of the β-cells already present that are in need of repair. These repaired insulin producing cells can contribute to the correction and maintenance of normal physiological glycemic levels.